News articles about KemPharm (NASDAQ:KMPH) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. KemPharm earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 44.7336497692714 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of research firms have issued reports on KMPH. Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a research report on Thursday, November 16th. ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. Finally, Canaccord Genuity reissued a “buy” rating and set a $7.00 price target on shares of KemPharm in a research report on Monday, September 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. KemPharm presently has an average rating of “Buy” and a consensus price target of $8.05.
Shares of KemPharm (KMPH) opened at $3.80 on Monday. KemPharm has a 1 year low of $2.45 and a 1 year high of $5.40. The company has a debt-to-equity ratio of -1.92, a quick ratio of 7.56 and a current ratio of 7.56. The stock has a market capitalization of $57.20 and a PE ratio of -1.30.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.